SOLODYN
PeakNDAORALTABLET, EXTENDED RELEASE
Approved
May 2006
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
4/8 — Partial
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SOLODYN is an extended-release oral tablet formulation of minocycline, a tetracycline antibiotic, approved for moderate to severe inflammatory acne vulgaris in patients aged 12 and older. The mechanism of action for acne treatment remains unknown, though minocycline is lipid-soluble and distributes into skin and sebum. SOLODYN provides delayed absorption compared to immediate-release minocycline formulations, achieving peak levels 3.5–4.0 hours post-dose.
$0.004BPart D
PeakStable
5.3 years to LOESOLODYN is a mature, peak-lifecycle product with minimal Part D volume (62 claims in 2023), indicating a small team focused on maintenance and specialty positioning rather than growth scaling.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Comparative Bioavailability Study of DFD-29 Capsules 40 mg Versus SOLODYN® Tablets 105 mg, Under Fasting & Fed Conditions in Healthy Adult Human Subjects
Started May 2022
24 enrolled
Pharmacokinetics
Career Relevance
SOLODYN offers limited career growth potential given its mature, low-volume peak-lifecycle status and approaching loss of exclusivity (5.3 years). Roles on this brand are best suited for professionals seeking stability in specialty dermatology or those transitioning to LOE management strategies; significant innovation or advancement opportunities are minimal.
Brand Manager (Specialty Dermatology)
Worked on SOLODYN at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.